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Chronic anticoagulation with vitamin K antagonists (VKAs) is recommended in patients 
with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Direct oral 
anticoagulants (NOACs) are an alternative to VKAs but there are limited data to 
support their use in HCM.  We sought to describe the pattern of use, thromboembolic 
events, bleeding and quality of life in patients with HCM and AF treated with NOACs.  
 
Methods: 
Data from patients treated with NOACs (n=99) and VKA (n=433) at 9 inherited cardiac 
diseases units were retrospectively collected. Annual rates of embolic events, serious 
bleeding and death were analysed and compared. Quality of life and treatment 
satisfaction were evaluated with SF-36 and SAFUCA questionnaires in 80 NOAC-treated 
and 57 VKA-treated patients.  
 
Results: 
After median follow-up of 63 months (IQR:26–109), thromboembolic events 
(TIA/stroke and peripheral embolism) occurred in 10% of patients on oral 
anticoagulation. Major/clinically relevant bleeding occurred in 3.8% and the global 
mortality rate was 23.3%. Thromboembolic event rate was 0.62 per 100 patient-years 
in the NOAC group vs. 1.59 in the VKA group [subhazard ratio (SHR) 0.32;95%CI:0.04–
2.45;p=0.27]. Major/clinically relevant bleeding occurred in 0.62 per 100 person-years 
















Quality of life scores were similar in both groups; however, NOAC-treated patients 
achieved higher scores in the SAFUCA. 
 
Conclusions: 
HCM patients with AF on NOACs showed similar embolic and bleeding rates to those 
on VKA. Although quality of life was similar in both groups, the NOAC group reported 
higher treatment satisfaction. 
 
Word count: 250 
 



















AF: atrial fibrillation  
CVA: cerebrovascular accident  
HCM: hypertrophic cardiomyopathy  
LA: Left atrium 
LVEF: Left ventricular ejection fraction 
LVOTO: Left ventricular outflow tract obstruction 
MWT: Maximal wall thickness 
NOACs: direct oral anticoagulants  
NYHA: New York Heart Association 
SAFUCA: satisfaction with Medical Care in Patients with Atrial Fibrillation  
SAM: Systolic anterior movement 
SHR: subhazard ratio 
TIA: transient ischaemic attack  
VKA: vitamin K antagonists  

























Hypertrophic cardiomyopathy (HCM) is the most common hereditary heart disease, 
and is the most frequent cause of sudden death among the young1. 
Atrial fibrillation (AF) is the most common arrhythmia of patients with HCM. HCM 
patients who develop AF have a very high risk of thromboembolic complications and 
approximately 27% of them will have an embolic event during their lifetime2.  Given 
the high incidence of stroke in patients with HCM and AF, clinical practice guidelines 
recommend that they should be anticoagulated with vitamin K antagonists (VKAs) in 
the absence of contraindications, irrespective of the risk score of scales used in 
patients with non-valvular AF (CHADS2 and CHA2DS2VASc)
3,4.  
Direct oral anticoagulants (NOACs) are recommended for patients with non-valvular AF 
and at least one additional risk factor for stroke based on non-inferiority or superiority 
to adjusted-dose warfarin in preventing stroke or systemic embolism, and reduced 
rates of haemorrhage achieved in clinical trials5. While HCM was not a formal 
contraindication to participate in NOACs trials, HCM patients tend to be younger and 
do not usually present with classical embolic risk factors. As a consequence, they were 
not adequately represented in these studies (mean age of participants in NOACs trials 
was ≥70 years, and mean CHADS2 score >2)
6-8.   
Despite the view that NOACs profile could be highly favourable for HCM patients 
(usually a young and very active population), data on NOACs use and effectiveness in 
this selected population are limited. 
The purpose of this study was 2-fold: first, to describe the pattern of use, clinical 
profile, thromboembolic events and haemorrhages in patients with HCM and AF 
















cohort of patients treated with a VKA. Second, we sought to evaluate quality of life and 
satisfaction with treatment of HCM patients on NOACs compared with those receiving 
a VKA. 
 
2.  Methods  
 
2.1 Study design and overview 
Data from a retrospective, multicentre longitudinal cohort were used. The study 
conformed to the principles of the Helsinki Declaration and was approved by the ethics 
committee of the Hospital Universitario Puerta de Hierro. The sponsors of the study 
had no role in study design, data collection, analysis or interpretation. F.D. and P.G-P. 
had access to all data and final responsibility to submit the article. The authors from 
each participating centre guarantee the integrity of data from their institution. All 
investigators have agreed to the article as written. 
 
2.2 Study population and participating centres 
The study cohort consisted of all consecutive patients with HCM and non-valvular AF 
treated with NOACs from the date they became commercially available in Spain 
(January 2011) until February 2016, followed at 9 Spanish Inherited Cardiac Disease 
Units (Appendix). 
HCM was defined as a maximum LV wall thickness ≥15 mm unexplained solely by 
loading conditions or ≥13 mm in first-degree relatives3. Non-valvular AF was defined as 
AF in the absence of rheumatic valvular disease or mechanical heart valves5. 
 A historical VKA-treated cohort was constructed and comprised all patients with HCM 
















participating centres: (i) Hospital Universitario Puerta de Hierro, Madrid, (ii) A Coruña 
University Hospital, A Coruña, and (iii) University Hospital Virgen de la Arrixaca, 
Murcia. These centres participated in recently published studies including analyses of 
AF appearance and stroke risk in HCM9,10. To avoid selection bias in the prescribed 
drug, the subgroup of patients who had initiated VKA therapy before NOACs were 
commercially available was also identified. Furthermore, to compare the quality of life 
and satisfaction with treatment with the NOAC group, a contemporary cohort of VKA-
treated patients who started VKA therapy in the same time period was identified.  
Only adult patients (≥18 years of age) were studied. Patients on treatment with NOACs 
or VKAs were identified from existing databases at each participating unit. Patients’ 
clinical data, treatments and events were obtained from their clinical records at 
participating centres.  
 
2.3 Clinical outcomes 
Cerebrovascular accident (CVA) was defined as a sudden onset focal neurological 
deficit lasting >24 h and caused by ischaemia. A focal neurological deficit lasting <24 h 
was considered transient ischaemic attack (TIA). An acute vascular occlusion of an 
extremity or organ, documented by means of imaging, surgery, or autopsy was 
considered peripheral embolism. The composite of CVA, TIA and peripheral embolism 
was defined as thromboembolic event, Major or clinically relevant bleeding was 
defined as a decrease in the haemoglobin level of at least 2 g/dL and/or an 
haemorrhage leading to an unscheduled visit to a healthcare centre or a temporary 
interruption of the anticoagulation therapy6-8. 
















Quality of life was evaluated with the SF-36 v2 questionnaire on health and welfare, 
and satisfaction with anticoagulation therapy with the SAFUCA (Satisfaction with 
Medical Care in Patients with Atrial Fibrillation) questionnaire.  
Each of the ten SF-36 health concepts was scored on a 0–100 scale. The maximum 
score of 100 is achieved when no disability is reported. Regarding the SAFUCA 
questionnaire, a maximum score of 100 implies full satisfaction in each of the 
addressed items. These questionnaires are widely used in clinical research and are 
valid and reliable in specific disease groups11,12.  
All patients with HCM and AF on treatment with NOACs were asked to complete the 
questionnaires and those who were available and agreed (n=80, 80%) were included in 
the study once informed written consent was obtained. In the same manner, a 
contemporary group of HCM patients who had initiated VKA therapy from 2008 
onwards was included at the 9 participating institutions. Each centre was requested to 
include a VKA patient per each NOAC-treated HCM patient who agreed to participate 
in the study. Because of this time-frame and centre restriction, the VKA group included 
57 individuals. Time of enrolment was 12 months to ensure that all potential patients 
fulfilling inclusion criteria were invited to participate in the study during their annual 
follow-up visit. No additional visits were scheduled and no modifications in their usual 
clinical follow-up were performed because of this study.  
 
2.5 Statistical analysis 
Results are presented as mean (standard deviation) for continuous variables with 
normal distribution, as median (interquartile range) for continuous variables without 
















analysis, Student’s t test and Mann-Whitney nonparametric test were used in two-
group comparisons for continuous variables, whereas Chi-square test or Fisher's exact 
test were used for categorical variables. Kaplan-Meier survival analysis was used to 
compare the treatment groups in the length of time after start of therapy until 
occurrence of death. All other clinical events were studied with competing-risks 
regression by the method of Fine and Gray, to take into account competing risks (e.g., 
death). A 2-tailed p value <0.05 was considered statistically significant. A propensity 
score analysis was thought to be unnecessary because most patients treated with VKA 
(88%) started the drug when NOACs were not available (before 2011), so they could 
not have been allocated to NOAC treatment. The entire analysis was performed using 




















3.  Results 
A total of 532 HCM patients with AF on VKA (n = 433) or NOAC (n = 99) treatment were 
retrospectively studied (Figure 1). Within the NOAC group, 47 patients were receiving 
rivaroxaban (47.5%), 29 dabigatran (29.3%) and 23 apixaban (23.2%). All patients in 
the VKA group were receiving acenocoumarol. 
More than 65% of patients in the NOAC group were male and almost 58% in the VKA 
group (p=0.16). Mean age at start of treatment was similar in both groups (61±14 vs. 
61±12; p=0.64) and most clinical and echocardiographic characteristics were 
comparable in both groups (Table 1). Clinical and echocardiographic characteristics of 
NOAC-treated patients and VKA-treated patients started on a VKA before NOACs 
became available (January 2011) were also comparable (Table 1). Regarding 
comorbidities, only renal disease was more prevalent in patients on NOACs than in 
those on a VKA (Table 1). Baseline treatment was also different between the two 
groups, with a higher use of concomitant antithrombotic therapy (clopidogrel and 
aspirin) in the VKA group (Table 1).  
The median follow-up time from the start of anticoagulation therapy to the last follow-
up was 63 months (17 months in the NOAC group and 78 months in the VKA group).  
In total, 57 of the NOAC-treated patients (57.6%) had been switched from a VKA while 
42 (42.4%) had been started directly on NOACs. Reported reasons for initiation of 
NOAC therapy were physician’s choice in 69 patients (69%), history of labile INR in 27 



















3.1 Clinical events 
Considering the NOAC and VKA groups together, thromboembolic events (TIA, CVA 
and peripheral embolism) occurred in 10% of HCM patients with AF on oral 
anticoagulation (10% of patients with paroxysmal AF, 9.4% of those with persistent AF 
and 10.4% with permanent AF; p=0.952) after a median follow-up of 63 months 
(interquartile range 26–109). During this period, major or clinically relevant bleeding 
occurred in 3.8% of cases (70% gastrointestinal, 15% genitourinary and 15% other 
sites; no intracranial bleedings occurred). The global mortality rate during follow-up 
was 23.3%. 
Patients who presented TIA, CVA or peripheral embolism had a higher prevalence of 
prior stroke or peripheral vascular disease than those without thromboembolic events 
after initiation of oral anticoagulation (31.8% vs. 6.6%; p<0.001 and 21.8% vs. 7.5%; 
p<0.001, respectively). Moreover, the left atrium (LA) diameter was greater in patients 
who presented TIA, CVA or peripheral embolism (51.73±7.55 mm vs. 48.82±7.97 mm; 
p=0.013). History of hypertension and diabetes was similar among patients with and 
without thromboembolic events (Table 1S).  
Annual all-cause mortality was 1.26 per 100 patients in the NOAC group and 3.81 in 
the VKA group [hazard ratio 0.55, 95% confidence interval (CI):0.13–2.30;p=0.41]. TIA 
and stroke rate in the NOAC group was 0 and 0.62 per 100 patient-years, while in the 
VKA group it was 0.25 and 1.06, respectively. The difference was not statistically 
significant [subhazard ratio (SHR) 0.46, 95%CI:0.06–3.62;p=0.46]. PE did not occur in 
any patient on NOAC treatment and it was present at an annual rate of 0.35 per 100 
















per 100 patient-years in the NOAC group and in 1.59 per 100 patient-years in the VKA 
group (SHR 0.32, 95%CI:0.04–2.45;p=0.27).   
Regarding bleeding, 0.62 per 100 patients treated with NOAC presented this 
complication per year, compared with 0.60 yearly per 100 patients on a VKA (SHR 1.28, 
95%CI:0.18–9.30;p=0.85)(Table 2).   
To avoid a drug indication bias, we performed a sub-analysis including those VKA 
patients who started VKA therapy before NOACs were available for thromboembolism 
prevention in patients with AF. The total number of patients who started VKA before 
2011 was 381. Annual all-cause mortality was 3.72 per 100 patient-years and TIA 
annual rate per 100 patients was 0.26. CVA and PE occurred at a rate of 1.11 and 0.36 
per 100 patients yearly, respectively. Globally, annual thromboembolic events were 
present in 1.65 per 100 patients on VKA, whereas bleeding presented an annual rate of 
0.56 per 100 patients-year. Again, no statistical differences were found between VKA 
and NOAC groups for all the variables (Table 2). 
The different NOAC subgroups (dabigatran, rivaroxaban and apixaban) did not present 
statistically significant differences regarding clinical events. No patients presented TIA 
or peripheral embolism; only one patient treated with rivaroxaban presented CVA 
(1/47: 2.1%) and another treated with apixaban experienced a clinically relevant 
bleeding event (gastrointestinal) (1/23: 4.3%). Two patients in the rivaroxaban group 
died (2/47: 4.2%; 1 due to heart failure and the other noncardiac). No deaths were 



















3.2 Quality of life and satisfaction with treatment 
Eighty patients from the 99 who had been started on NOACs accepted to answer the 
SF-36 and SAFUCA questionnaires. Additionally, a contemporary group of 57 VKA-
treated patients who had started a VKA from November 2008 onwards were studied. 
Both groups presented similar clinical characteristics including age, gender, 
comorbidities, echocardiographic characteristics and baseline treatments. Only LA 
diameter was slightly greater in the NOAC group (Table 2S). 
The SF-36 questionnaire results were similar in both groups regarding all the included 
items (physical component, mental component, physical functioning, role-physical, 
bodily pain, global health, vitality, social functioning, role-emotional and mental 
health).  Specific scores are shown in Table 3.  
Nonetheless, the NOAC group achieved a higher score in most of the SAFUCA 
questionnaire items, which were graded according to the degree of satisfaction (%). 
These included convenience of the medication (83.86±17.80% vs. 76.3±23.02%; 
p=0.03), interference with daily life (92.34±11.16% vs. 79.21±19.07%; p<0.001), 
adverse effects (88.24±18.75% vs. 75.87±25.14%; p=0.001) and general opinion of the 
drug (84.58±16.46% vs. 73.69±22.44%; p=0.001). SAFUCA scores on medical follow-up 


















4.  Discussion 
This study describes the clinical characteristics as well as the thromboembolic and 
bleeding events in HCM patients with AF on NOAC therapy and compares them with a 
historical cohort of patients treated with a VKA. Additionally, it provides data about 
quality of life and satisfaction with treatment of HCM patients on NOACs compared 
with those receiving a VKA. The results of the study show that HCM patients receiving 
NOACs have similar embolic and bleeding rates to those receiving a VKA and, at the 
same time, have higher satisfaction with treatment despite reporting similar quality of 
life.   
 
AF is the most common arrhythmia in patients with HCM. Prospective data show that 
after 10 years of follow-up, 22% to 30% of HCM patients develop AF2,13,14. AF has a 
strong impact on HCM clinical course and on patients’ quality of life. Due to very high 
embolic risk, chronic oral anticoagulation is recommended in all HCM patients with AF. 
This recommendation is based on observational studies showing that warfarin-treated 
HCM patients with AF presented about one half of embolic events (18% vs 31%) and 
stroke (10% vs 39%) to those not receiving anticoagulation treatment13. Currently, ESC 
HCM clinical guidelines recommend VKAs as the anticoagulant agents of choice in HCM 
and restricts NOACs use to patients who cannot maintain INR in the therapeutic range 
or have had VKA-related side effects3. However, the latest ESC AF guidelines state that 
NOACs are broadly preferable to VKAs in the vast majority of patients with non-
valvular AF5, based on clinical trials that have shown non-inferiority compared with 
VKAs, as well as better safety and less intracranial haemorrhage6-8. Furthermore, 
















VKAs15, and that non-valvular AF patients are more satisfied with medical care when 
treated with NOACs12.  
While HCM patients were not formally excluded from NOACs trials, the number of 
HCM patients included in these studies is unknown and presumably was low because 
they tend to be younger (mean age of patients included in NOACs trials was >70) and 
do not exhibit the traditional CHADS2 factors required to participate in NOAC studies. 
Therefore, little data currently supports the use of NOACs in HCM despite the notion 
that NOACs could represent a valid alternative to VKA in this younger, active 
population.    
 
4.1 NOAC versus VKA for the prevention of clinical events in patients with HCM and AF 
The annual rate of thromboembolic events (TIA, CVA, peripheral embolism) was 1.59 
per 100 patient years in the VKA group and 0.62 in the NOAC group, although this 
difference did not reach statistical significance. While meta-analyses with pooled 
results from NOAC trials have shown a significant reduction of stroke and systemic 
embolism for the general population with non-valvular AF16, the sample of patients in 
those studies was considerably larger.  
NOAC trials have also demonstrated a significant reduction in haemorrhagic stroke 
with NOACs and in meta-analyses there was a trend towards reduced major 
bleeding16. In our study, major or clinically relevant bleeding per 100 patient-years was 
similar in both groups, but the bleeding rates were substantially lower as compared 
with those found in the NOACs trials6-8. However, HCM patients in our study were 
younger (mean age 61) and bleeding rates were similar to those reported in patients 
















our study, which may have also been influenced by age and the fact that hypertension 
was present in 54% of patients in our cohort, as compared to 80–90% of patients 
included in the NOAC trials 6-8. 
A recent study that used a large American commercial insurance database evaluated 
stroke and bleeding risks in patients with HCM and AF treated with NOACs and VKAs19. 
In line with our findings, the data from this study suggested that this patient group 
could be safely treated with NOACs. In contrast to our study, the aforementioned 
study did not provide patients’ clinical characteristics, and its design (information was 
extracted from billing codes) made it impossible to know whether factors that may 
predispose to cardioembolism, such as mitral valve dysfunction, left atrial enlargement 
and left ventricular dysfunction, or factors that confer an increased risk of bleeding 
including concomitant antiplatelet therapy, were balanced between groups. In the 
present study, we found that clinical characteristics were well balanced between VKA 
and NOAC groups except for kidney disease (higher in the NOAC group) and 
concomitant antiplatelet therapy (higher in the VKA group). Both the American study 
and ours are probably underpowered in terms of number of individuals to 
demonstrate superiority of NOACs over VKAs in HCM patients with AF. However, the 
results of the American study taken together with ours would favour the upgrading of 
NOACs to a similar level of recommendation to VKAs in guidelines because a clinical 
trial with both agents is unlikely to be carried out and current VKA recommendation in 
HCM also arises from observational findings. 
The fact that impaired renal function was more prevalent in the NOAC group was 
surprising, although this includes patients with mild renal disease in whom NOACs can 
















also played a role in this finding. Moreover, the use of concomitant antithrombotic 
therapy was higher in the VKA group. Regrettably, information about indications for 
antiplatelet therapy and history of coronary artery disease was not available. However, 
patients treated with a VKA had a 56.6% prevalence of hypertension, and 20.8% of 
diabetes mellitus versus 47.5% and 16.2% in the NOAC group, respectively. Although 
these differences did not reach statistical significance, when assessing both 
cardiovascular risk factors together (hypertension and/or diabetes mellitus), the VKA 
group presented a prevalence of 60.3% versus 49.5% in the NOAC group (p=0.05). As 
the burden of cardiovascular disease risk factors seems to be higher in the first group, 
this might explain why antiplatelet therapy was more frequently used. Furthermore, 
an indication bias could be present as the NOAC cohort belongs to a more recent time 
period in which antiplatelet therapy is not generally advocated for primary prevention 
in patients receiving anticoagulants. Nevertheless, the bleeding risk of the VKA group 
was not higher than that in patients on NOAC therapy. 
 
4.2 Quality of life and treatment satisfaction  
Current guidelines only consider NOACs in HCM when INR optimal range is not 
achieved with VKAs, or when side effects occur. In our study, only 28% of the patients 
treated with NOACs had previous history of labile INR and just 12% experienced 
bleeding or intolerance to VKA; the remaining 69% initiated NOAC therapy due to 
physician or patient’s choice.  
Mean age of patients included in our study was approximately 61 years in both groups, 
so many were presumably still in employment. In contrast to NOACs, VKA treatment 
















important impact on lifestyle and is also time consuming. Therefore, it is not surprising 
that HCM patients would prefer NOACs to VKAs on the assumption that they are 
equally effective and safe. 
Similar scores were obtained by patients in the two groups who completed the SF-36 
questionnaire. SF-36 addresses different health concepts that are relevant to HCM 
patients, including physical functioning, role limitations due to physical problems, 
bodily pain, general health perceptions, vitality, social functioning, role limitations due 
to emotional problems, and mental health. HCM patients have been assessed with the 
SF-36 questionnaire in previous studies20,21, and it has been observed that quality of 
life is substantially impaired when compared with that of the general population. We 
did not observe that quality of life as assessed by the SF-36 was better in NOAC-
treated patients, suggesting that quality of life in HCM patients mainly depends on the 
condition itself rather than on the medication that patients receive.  
Conversely, the SAFUCA questionnaire generated higher scores in the NOAC group. 
NOAC-treated patients thought that NOACs were more convenient, had less 
interference with daily life activities and had lower rate of adverse events, compared 
with patients treated with a VKA. Nonetheless, no differences were found regarding 
perceived efficacy and medical follow-up. These results suggest that NOAC-treated 
patients are more satisfied with treatment than VKA-treated patients, but both groups 
perceive that the two drugs are equally useful and medical attention is the same 
irrespective of the baseline treatment.  
Interestingly, the SAFUCA questionnaire was recently used in a Spanish study with 
more than 1,200 anticoagulated patients with non-valvular AF12, and in that study the 

















4.3 Clinical predictors of thromboembolism in anticoagulated HCM patients with AF 
In our study, 10% of anticoagulated HCM patients with AF presented thromboembolic 
events during follow-up, similar to thromboembolic rates described in other warfarin-
treated HCM series. 
LA diameter was greater in subjects who had thromboembolic events, which is also 
consistent with previous studies9,22. The present study also supports recent ESC 
guidelines that advise against CHA2DS2-VASc score use in HCM with AF, as the group of 
patients who suffered thromboembolic events did not present a higher prevalence of 
vascular risk factors such as hypertension or diabetes3. Nonetheless, it should be noted 
that peripheral vascular disease and stroke before initiating anticoagulant therapy 
were more prevalent among patients with thromboembolic events during follow-up.  
 
5.  Limitations 
We acknowledge that the number of patients included in this study is limited and 
therefore our study is underpowered to statistically demonstrate equivalency or 
superiority of NOACs over VKAs in HCM individuals with AF. Patients on NOACs belong 
to a more contemporary cohort than those treated with VKA, which also have a longer 
follow-up period. In this latter group, time in therapeutic range was not available. 



















6.  Conclusions 
Our results suggest that NOACs are safe and effective for the prevention of 
cardioembolism in patients with HCM and AF. Moreover, compared with those treated 
with a VKA, HCM patients treated with NOACs report higher satisfaction with 
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Table 1. Clinical and echocardiographic characteristics in 532 HCM patients with AF 
according to anticoagulation therapy  
 
 NOACs  
(n = 99) 
VKA  
(n = 433) 
VKA  
<2011 


















Male sex 65.7% 58.0% 56.7% 0.16 0.11 
Hypertension 47.5 % 56.6 % 57.2% 0.14 0.11 
Diabetes 16.2% 20.8% 20.5% 0.30 0.34 
Peripheral 
vascular disease 
6.1% 9.7% 10.5% 0.25 0.18 
Liver disease 2% 5.8% 5.5% 0.13 0.15 
Renal disease 13.3% 6.7% 6.3% 0.03 0.02 
NYHA I 42.1% 38.9% 37.1% 0.56 0.37 
NYHA II-IV 57.9% 61.1% 62.9% 0.56 0.37 
Non sustained VT  31.9% 31.0% 31.0% 0.88 0.88 
MWT (mm) 20.62 ± 
4.53 
20.15 ± 4.63 20.05 ± 
4.64 
0.64 0.30 









Obstructive HCM,  
%* 
26.7% 29.5% 27.4% 0.62 0.90 







SAM of the mitral 
valve  
40.9% 41.4% 40.0% 0.93 0.88 
LA diameter (mm) 48.66 
±7.85 
49.21 ± 7.92 49.20 
±7.95 
0.54 0.44 
Aspirin 13.7% 24.5% 24.0% 0.02 0.03 
Clopidogrel 0% 5.1% 5.8% 0.03 0.02 
Beta-blockers 82.6% 77.4% 75.6% 0.27 0.15 
Calcium channel 
blockers 
15.2% 31.2% 31.8% 0.002 0.002 
Amiodarone 43% 37.2% 37.5% 0.29 0.33 
Sotalol 2.2% 8.3% 10.6% 0.07 0.03 
Disopyramide 13.8% 7.4% 6.6% 0.04 0.02 
LVEF: Left ventricular ejection fraction, LA: Left atrium, LVOTO: Left ventricular outflow tract 
obstruction, MWT: Maximal wall thickness, NYHA: New York Heart Association, SAM: Systolic 
anterior movement, NOAC: Direct oral anticoagulants; VKA: vitamin K antagonist; VKA<2011: 
VKA-treated patients started on VKA before 2011, VT: Ventricular tachycardia. 
 

















Table 2. Clinical events in NOAC-treated and VKA-treated HCM patients with AF 
 
 NOAC   
(n = 99) 
VKA  
(n = 433) 
VKA  
< 2011 



















Transient ischaemic attack  
(per 100 patient-years) 
 
0 0.25 0.26 - - - - - - 
Stroke 
(per 100 patient-years) 
 
0.62 1.06 1.10 0.46* 0.06–3.62 0.46 0.41* 0.05–3.29 0.40 
Peripheral embolism 
(per 100 patient-years) 
 
0 0.35 0.36 - - - - - - 
Thromboembolic event 
(per 100 patient-years) 
 
0.62 1.59 1.65 0.32* 0.04–2.45 0.27 0.29* 0.04–2.21 0.23 
Major/clinically relevant 
bleeding on anticoagulation 
(per 100 patient-years) 
0.62 0.60 0.56 1.28* 0.18–9.30 0.85 1.98* 0.32–12.49 0.47 
 Gastrointestinal (%) 100  68.4 68.8       
 Intracranial (%) 0 0 0       
 Genitourinary (%) 0 15.8 18.7       
 Others (%) 0 15.8 12.5       
Death 
(per 100 patient-years) 
 
1.26 3.81 3.72 0.55 0.13–2.30 0.41 0.69 0.16–2.93 0.61 
* Subhazard ratio 
HR: Hazard ratio, SHR: Subhazard ratio; NOAC: Direct oral anticoagulants; VKA: vitamin K antagonist ; VKA<2011: VKA-treated patients started 
















Table 3. SF36 and SAFUCA questionnaires scores in 137 HCM patients with AF treated 
with NOACs (n = 80) or VKA (n = 57) 
 
SF36 QUESTIONNAIRE 




43.06 ± 9.74 41.07 ± 10.07 0.26 
Mental component 
 
49.18 ± 11.71 49.96± 9.91 0.69 
Physical functioning 
 
42.10± 10.87 40.40 ± 10.86 0.37 
Role-Physical 
 
43.98 ± 11.50 43.40 ± 12.24 0.78 
Bodily pain 
 
51.53 ± 11.77 48.35 ± 11.98 0.13 
Global health 
 
38.94 ± 10.20 37.03 ± 9.84 0.28 
Vitality 
 
48.42± 11.45 47.2 ± 11.04 0.54 
Social functioning 
 
47.42 ± 11.43 47.34 ± 11.99 0.97 
Role-Emotional  
 
47.05 ± 11.60 47.21 ± 11.37 0.94 
Mental Health 
 
47.61 ± 11.89 48.87 ± 9.1 0.51 
 
SAFUCA QUESTIONNAIRE 
 NOAC  (% satisfaction) VKA  (% satisfaction) p-
value 
Efficacy of medication 
 
80.70 ± 16.65 75.58 ± 20.95 0.12 
Convenience of medication 
 
83.86 ± 17.80 76.3  ± 23.02 0.03 
Interference of medication 
with daily life 
92.34 ± 11.16 79.21 ± 19.07 <0.001 
Adverse effects caused by 
the anticoagulant 
medication 
88.24 ± 18.75 75.87 ± 25.14 0.001 
Medical follow-up of the 
disease 
89.32 ± 15.43 87.57 ± 18.50 0.55 
General opinion on the 
medication and health 
condition 
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(iv) Hospltal Clinico, Malaga 
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(viii) Hospital General Universitario, Alicante 
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Figure 1 
